The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system

Clinical and Experimental Immunology

Volumn 121, Issue 1, 2000, Pages 69-76

  Langeggen, H ^a   Pausa, M ^c   Johnson, E ^a   Casarsa, C ^b   Tedesco, Francesco ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Dept of Physiology and Pathology ^*

Author keywords

C7; Cytokines; Endothelial cells

Indexed keywords

CYCLOHEXIMIDE;

ARTICLE; CALCULATION; CELL CULTURE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DOWN REGULATION; ELECTROPHORETIC MOBILITY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS;

ANIMALS; CELLS, CULTURED; COMPLEMENT C7; ENDOTHELIUM, VASCULAR; GOATS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-1;

EID: 0033945557     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01238.x     Document Type: Article

References (36)

1. Morris KM, Aden DP, Knowles BB et al. Complement biosynthesis by the human hepatoma derived cell line HepG2. J Clin Invest 1982; 70:906-13.
2. Colten HR, Garnier G. Regulation of complement protein gene expression. In: Volanakis JE, Frank MM, eds. The human complement system in health and disease. New York: Marcel Dekker, 1998:217-40.
3. Johnson E, Hetland G. Mononuclear phagocytes have the potential to synthesize the complete functional complement system. Scand J Immunol 1988; 27:489-93.
4. Gulati P, Lemercier C, Guc D et al. Regulation of the C1 subcomponents and C1-inhibitor. Behring Inst Mitt 1993; 93:193-203.
5. Ueki A, Sai T, Oka H et al. Biosynthesis and secretion of the third component of complement by human endothelial cells in vitro. Immunology 1987; 61:11-14.
6. Warren HB, Pantazis P, Davies PF. The third component of complement is transcribed and secreted by cultured human endothelial cells. Am J Pathol 1987; 129:9-13.
7. Brooimans RA, Hiemstra PS, van der Ark AAJ et al. Biosynthesis of complement factor H by human umbilical endothelial cells. Regulation by T cell growth factor and IFN-γ. J Immunol 1989; 142:2024-30.
8. Julen N, Dauchel H, Lemercier C et al. In vitro biosynthesis of complement factor I by human endothelial cells. Eur J Immunol 1992; 22:213-7.
9. Ripoche J, Mitchell JA, Erdei A et al. Interferon γ induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J Exp Med 1988; 168:1917-22.
10. Dauchel H, Julen N, Lemercier C et al. Expression of complement alternative pathway proteins by endothelial cells. Differential regulation by interleukin 1 and glucocorticoids. Eur J Immunol 1990; 20:1669-75.
11. Johnson E, Hetland G. Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro. Scand J Immunol 1991; 33:667-71.
12. Mollnes TE, Lea T, Harboe M et al. Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985; 22:183-95.
13. Berge V, Johnson E, Nazir M. Effect of gamma-interferon on the synthesis of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro. APMIS 1994; 102:554-8.
14. Wurzner R, Joysey VC, Lachmann PJ. Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. J Immunol 1994; 152:4624-9.
15. Naughton MA, Walport MJ, Wurzner R et al. Organ-specific contribution to circulating C7 levels by the bone marrow and liver in humans. Eur J Immunol 1996; 26:2108-12.
16. Hetland G, Johnson E, Falk RJ et al. Synthesis of complement components C5, C6, C7, C8 and C9 in vitro by human monocytes and assembly of the terminal complement complex. Scand J Immunol 1986; 24:421-8.
17. Hogasen AKM, Wurzner R, Abrahamsen TG et al. Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol 1995; 154:4734-40.
18. Tedesco F, Roncelli L, Petersen BH et al. Two distinct abnormalities in patients with C8α-γ deficiency. Low level of C8β chain and presence of dysfunctional C8α-γ subunit. J Clin Invest 1990; 86:884-8.
19. Jaffe EA, Nachman RL, Becker CG et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphological and immunological criteria. J Clin Invest 1973; 52:2745-56.
20. Perisutti S, Tedesco F. Effect of cytokines on the secretion of the fifth and eighth complement components by HepG2 cells. Int J Clin Lab Res 1994; 24:45-48.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227:680-5.
22. Tedesco F, Pausa M, Nardon E et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185:1619-27.
23. Harrison RA, Lachmann PJ. Complement technology. In: Weir DM, Herzenberg LA, Blackwell C, Herzenberg Leonore A, eds. Handbook of experimental immunology, Vol. 2, chapter 39. London: Blackwell Scientific Publications, 1986.
24. Montinaro V, Serra L, Perisutti S et al. Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines. Kidney Int 1995; 47:829-36.
25. Ponte P, Ng SY, Engel J et al. Evolutionary conservation in an untranslated region of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucl Acid Res 1984; 12:1687-96.
26. Jaffe EA. Biochemistry, immunology and cell biology of endothelium. In: Colman RW, Hirsch J, Marder VJ, Saltzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Co, 1994:718-44.
27. Hindmarsch EJ, Marks RM. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlaying endothelial cells. J Immunol 1998; 160:6128-36.
28. Lachmann PJ, Thompson RA. Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med 1970; 131:643-57.
29. Platonov AE, Würzner R, Beloborodov VB et al. Paradoxical reconstitution of complement activity following plasma transfusion of an individual with deficiency of the seventh component of complement. Immunology 1994; 81:142-8.
30. Würzner R, Platonov AE, Beloborodov VB et al. How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion. Immunology 1996; 88:407-11.
31. Fernie BA, Würzner R, Orren A et al. Molecular basis of combined subtotal deficiencies of C6 and C7. Their effects in combination with other C6 and C7 deficiencies. J Immunol 1996; 157:3648-57.
32. Brooimans RA, van der Ark AAJ, Buurman WA et al. Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-γ and IL-1. J Immunol 1990; 144:3835-40.
33. Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and pathophysiology of vascular disorders. Blood 1998; 91:3527-61.
34. Podack ER, Kolb WP, Müller-Eberhard HJ. The C5b-9 complex: formation, isolation, and inhibition of its activity by lipoprotein and S-protein of human serum. J Immunol 1978; 120:1841-8.
35. Berge V, Johnson E, Berge KE. Interleukin-1α, interleukin 6 and tumor necrosis factor α increase the synthesis and expression of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro. APMIS 1996; 104:213-9.
36. Pepys MP. Acute phase proteins. In: Roitt IM, Delves PJ, eds. Encyclopedia of immunology. London: Academic Press, 1992:16-18.